Following a full submission
aflibercept (Eylea®) is accepted for use within NHS Scotland.
Indication under review: in adults for the treatment of neovascular (wet) age-related macular degeneration.
In two pivotal randomised controlled studies the non-inferiority of aflibercept versus monthly injections of another anti-VEGF treatment was demonstrated for the primary endpoint; proportion of patients who maintained vision at week 52.
The economic analysis submitted by the company related to the use of aflibercept in patients with wet AMD who have not previously been treated with anti-VEGF therapy.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of aflibercept. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland.
|Drug Name:||aflibercept (Eylea)|
|SMC Drug ID:||857/13|
|Manufacturer:||Bayer plc/Bayer Schering Pharma|
|Indication:||For the treatment of neovascular (wet) age-related macular degeneration (AMD).|
|Sub Category:||11.8 Miscellaneous ophthalmic preparations|
|Submission Type:||Full submission|
|Date Advice Published:||8 April 2013|